Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Impact · against what's priced in

The approval of FAYUVI (UX111) is a positive catalyst for Ultragenyx because the market had previously declined to price in the success of this regulatory milestone. The addition of a Priority Review Voucher provides a non-dilutive cash boost to a company currently struggling with high cash burn and recent clinical failures.

RARE+0.60

Challenges what's priced in

The price assumes